{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T02:02:02Z","timestamp":1779933722299,"version":"3.53.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NCI","award":["5 P50 CA172012"],"award-info":[{"award-number":["5 P50 CA172012"]}]},{"name":"NCI","award":["CA201250"],"award-info":[{"award-number":["CA201250"]}]},{"name":"NCI","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Fluorine 18-labelled tetrafluoroborate ([<jats:sup>18<\/jats:sup>F]TFB) is a substrate for the sodium\/iodide symporter. In thyroid cancer, [<jats:sup>18<\/jats:sup>F]TFB-PET\/CT may be an alternative to iodine imaging to evaluate the extent of disease, eligibility for radioiodine treatment, and success of redifferentiation therapies. We report the results of a pilot study to determine tumor uptake of [<jats:sup>18<\/jats:sup>F]TFB and compare its properties to [<jats:sup>124<\/jats:sup>I]IodinePET\/CT in patients with metastatic thyroid cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Five patients were included in a prospective study. All patients received PET\/CT 1\u00a0h after injection of 356\u2009\u00b1\u200912 MBq [<jats:sup>18<\/jats:sup>F]TFB and were given 230\u2009\u00b1\u20099 MBq [<jats:sup>124<\/jats:sup>I]Iodine orally on the same day, followed by PET\/CT after 48\u00a0h. Before redifferentiation therapy, patients underwent an additional baseline [<jats:sup>124<\/jats:sup>I]Iodine PET\/CT. Cases were analyzed by two board-certified specialists. Detection rates and Spearman correlation for [<jats:sup>18<\/jats:sup>F]TFB and [<jats:sup>124<\/jats:sup>I]Iodine were calculated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Three patients had poorly differentiated thyroid cancer and received trametinib in a redifferentiation trial. Two patients had papillary thyroid cancer and did not receive redifferentiation therapy. Of the 33 lesions seen before\/without redifferentiation therapy, 19 (58%) were visible on [<jats:sup>18<\/jats:sup>F]TFB and 30 (91%) on [<jats:sup>124<\/jats:sup>I]Iodine imaging. In the patients who underwent redifferentiation therapy, 48 lesions were newly seen on [<jats:sup>124<\/jats:sup>I]Iodine PET\/CT with a median SUV<jats:sub>max<\/jats:sub> of 3.3 (range, 0.4\u2013285.0). All of these lesions were [<jats:sup>18<\/jats:sup>F]TFB-negative.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>[<jats:sup>18<\/jats:sup>F]TFB failed to predict radioactive iodine uptake in patients with poorly differentiated thyroid cancer who underwent redifferentiation therapy with trametinib. It is unclear whether such discrepancies may also occur in other redifferentiation therapies or may even be encountered in redifferentiation-na\u00efve thyroid cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration number<\/jats:title>\n                <jats:p>NCT03196518, registered on June 22, 2017.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13550-024-01138-x","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T15:02:02Z","timestamp":1728399722000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["[18F]TFB PET\/CT misses intense [124I]iodine-avid metastases after redifferentiation therapy in metastatic thyroid cancer"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4164-4104","authenticated-orcid":false,"given":"Philipp","family":"Backhaus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith S.","family":"Pentlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan L","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Mauguen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A","family":"Fagin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naga Vara Kishore","family":"Pillarsetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge K.","family":"Lyashchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Burnazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald A.","family":"Ghossein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalini","family":"Chhabra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murad","family":"Abusamra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiko","family":"Sch\u00f6der","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"O\u2019Donoghue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravinder K.","family":"Grewal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,8]]},"reference":[{"key":"1138_CR1","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1002\/cncr.20087","volume":"100","author":"M Volante","year":"2004","unstructured":"Volante M, Landolfi S, Chiusa L, Palestini N, Motta M, Codegone A, Torchio B, Papotti MG. Poorly differentiated carcinomas of the thyroid with trabecular, insular, and solid patterns. Cancer. 2004;100:950\u20137. https:\/\/doi.org\/10.1002\/cncr.20087.","journal-title":"Cancer"},{"key":"1138_CR2","doi-asserted-by":"publisher","first-page":"R209","DOI":"10.1530\/erc-17-0542","volume":"25","author":"A Berdelou","year":"2018","unstructured":"Berdelou A, Lamartina L, Klain M, Leboulleux S, Schlumberger M. Treatment of refractory thyroid Cancer. Endocr-relat Cancer. 2018;25:R209\u201323. https:\/\/doi.org\/10.1530\/erc-17-0542.","journal-title":"Endocr-relat Cancer"},{"key":"1138_CR3","doi-asserted-by":"publisher","first-page":"R113","DOI":"10.1530\/erc-19-0491","volume":"1","author":"C Buffet","year":"2020","unstructured":"Buffet C, Wassermann J, Hecht F, Leenhardt L, Dupuy C, Groussin L, Lussey-Lepoutre C. Redifferentiation of Radioiodine-Refractory thyroid cancers. Endocr-relat Cancer. 2020;1:R113\u201332. https:\/\/doi.org\/10.1530\/erc-19-0491.","journal-title":"Endocr-relat Cancer"},{"key":"1138_CR4","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1007\/s00259-007-0660-6","volume":"35","author":"HTT Phan","year":"2008","unstructured":"Phan HTT, Jager PL, Paans AMJ, Plukker JTM, Sturkenboom MGG, Sluiter WJ, Wolffenbuttel BHR, Dierckx RAJO, Links TP. The diagnostic value of 124I-PET in patients with differentiated thyroid Cancer. Eur J Nucl Med Mol I. 2008;35:958\u201365. https:\/\/doi.org\/10.1007\/s00259-007-0660-6.","journal-title":"Eur J Nucl Med Mol I"},{"key":"1138_CR5","doi-asserted-by":"publisher","first-page":"66","DOI":"10.4274\/2017.26.suppl.07","volume":"26","author":"R Kuker","year":"2016","unstructured":"Kuker R, Sztejnberg M, Gulec S. I-124 imaging and Dosimetry. Malecular Imaging Radionucl Ther. 2016;26:66\u201373. https:\/\/doi.org\/10.4274\/2017.26.suppl.07.","journal-title":"Malecular Imaging Radionucl Ther"},{"key":"1138_CR6","first-page":"1557","volume":"37","author":"KS Pentlow","year":"1996","unstructured":"Pentlow KS, Graham MC, Lambrecht RM, Daghighian F, Bacharach SL, Bendriem B, Finn RD, Jordan K, Kalaigian H, Karp JS, et al. Quantitative imaging of Iodine-124 with PET. J Nucl Med : off Publ Soc Nucl Med. 1996;37:1557\u201362.","journal-title":"J Nucl Med : off Publ Soc Nucl Med"},{"key":"1138_CR7","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1007\/s00259-010-1601-3","volume":"37","author":"H Youn","year":"2010","unstructured":"Youn H, Jeong JM, Chung J-KA, New PET, Probe. 18F-Tetrafluoroborate, for the Sodium\/Iodide Symporter: possible impacts on Nuclear Medicine. Eur J Nucl Med Mol I. 2010;37:2105\u20137. https:\/\/doi.org\/10.1007\/s00259-010-1601-3.","journal-title":"Eur J Nucl Med Mol I"},{"key":"1138_CR8","doi-asserted-by":"publisher","unstructured":"Nucl Med Commun 2011, 32, 98\u2013105, https:\/\/doi.org\/10.1097\/mnm.0b013e3283419540.","DOI":"10.1097\/mnm.0b013e3283419540"},{"key":"1138_CR9","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.7150\/thno.24997","volume":"8","author":"H Jiang","year":"2018","unstructured":"Jiang H, DeGrado TR. [18F]tetrafluoroborate ([18F]TFB) and its analogs for PET imaging of the Sodium\/Iodide Symporter. Theranostics. 2018;8:3918\u201331. https:\/\/doi.org\/10.7150\/thno.24997.","journal-title":"Theranostics"},{"key":"1138_CR10","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.2967\/jnumed.117.192252","volume":"58","author":"J O\u2019Doherty","year":"2017","unstructured":"O\u2019Doherty J, Jauregui-Osoro M, Brothwood T, Szyszko T, Marsden PK, O\u2019Doherty MJ, Cook GJR, Blower PJ, Lewington V. 18F-Tetrafluoroborate, a PET probe for imaging Sodium\/Iodide Symporter expression: whole-body Biodistribution, Safety, and Radiation Dosimetry in thyroid Cancer patients. J Nucl Med. 2017;58:1666\u201371. https:\/\/doi.org\/10.2967\/jnumed.117.192252.","journal-title":"J Nucl Med"},{"key":"1138_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/bf02294183","volume":"65","author":"DG Bonett","year":"2000","unstructured":"Bonett DG, Wright TA. Sample size requirements for estimating Pearson, Kendall and Spearman Correlations. Psychometrika. 2000;65:23\u20138. https:\/\/doi.org\/10.1007\/bf02294183.","journal-title":"Psychometrika"},{"key":"1138_CR12","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1007\/s00259-010-1523-0","volume":"37","author":"M Jauregui-Osoro","year":"2010","unstructured":"Jauregui-Osoro M, Sunassee K, Weeks AJ, Berry DJ, Paul RL, Cleij M, Banga JP, O\u2019Doherty MJ, Marsden PK, Clarke SEM, et al. Synthesis and biological evaluation of [18F]tetrafluoroborate: a PET imaging Agent for thyroid disease and reporter Gene Imaging of the Sodium\/Iodide Symporter. Eur J Nucl Med Mol I. 2010;37:2108\u201316. https:\/\/doi.org\/10.1007\/s00259-010-1523-0.","journal-title":"Eur J Nucl Med Mol I"},{"key":"1138_CR13","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13550-015-0148-5","volume":"5","author":"JM Marti-Climent","year":"2015","unstructured":"Marti-Climent JM, Collantes M, Jauregui-Osoro M, Quincoces G, Prieto E, Bilbao I, Ecay M, Richter JA, Pe\u00f1uelas I. Radiation Dosimetry and Biodistribution in Non-human Primates of the Sodium\/Iodide PET ligand [18F]-Tetrafluoroborate. Ejnmmi Res. 2015;5:70. https:\/\/doi.org\/10.1186\/s13550-015-0148-5.","journal-title":"Ejnmmi Res"},{"key":"1138_CR14","doi-asserted-by":"publisher","unstructured":"Jiang H, Schmit NR, Koenen AR, Bansal A, Pandey MK, Glynn RB, Kemp BJ, Delaney KL, Dispenzieri A, Bakkum-Gamez JN, et al. Safety, Pharmacokinetics, Metabolism and Radiation Dosimetry of 18F-Tetrafluoroborate (18F-TFB) in healthy human subjects. Ejnmmi Res. 2017;7. https:\/\/doi.org\/10.1186\/s13550-017-0337-5.","DOI":"10.1186\/s13550-017-0337-5"},{"key":"1138_CR15","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1007\/s00259-020-04727-9","volume":"47","author":"M Dittmann","year":"2020","unstructured":"Dittmann M, Carvalho JMG, Rahbar K, Sch\u00e4fers M, Claesener M, Riemann B, Seifert R. Incremental diagnostic value of [18F]tetrafluoroborate PET-CT compared to [131I]Iodine Scintigraphy in Recurrent differentiated thyroid Cancer. Eur J Nucl Med Mol I. 2020;47:2639\u201346. https:\/\/doi.org\/10.1007\/s00259-020-04727-9.","journal-title":"Eur J Nucl Med Mol I"},{"key":"1138_CR16","doi-asserted-by":"publisher","unstructured":"Ventura D, Dittmann M, B\u00fcther F, Sch\u00e4fers M, Rahbar K, Hescheler D, Claesener M, Schindler P, Riemann B, Seifert R, et al. Diagnostic performance of [18F]TFB PET\/CT compared with therapeutic activity [131I]Iodine SPECT\/CT and [18F]FDG PET\/CT in recurrent differentiated thyroid carcinoma. J Nucl Med. 2023;jnumed123266513. https:\/\/doi.org\/10.2967\/jnumed.123.266513.","DOI":"10.2967\/jnumed.123.266513"},{"key":"1138_CR17","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1097\/rlu.0000000000001977","volume":"43","author":"S Samnick","year":"2018","unstructured":"Samnick S, Al-Momani E, Schmid J-S, Mottok A, Buck AK, Lapa C. Initial clinical investigation of [18F]Tetrafluoroborate PET\/CT in comparison to [124I]iodine PET\/CT for imaging thyroid Cancer. Clin Nucl Med. 2018;43:162\u20137. https:\/\/doi.org\/10.1097\/rlu.0000000000001977.","journal-title":"Clin Nucl Med"},{"key":"1138_CR18","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.2967\/jnumed.115.169649","volume":"57","author":"M Ruhlmann","year":"2016","unstructured":"Ruhlmann M, Jentzen W, Ruhlmann V, Pettinato C, Rossi G, Binse I, Bockisch A, Rosenbaum-Krumme S. High level of Agreement between Pretherapeutic 124I PET and intratherapeutic 131I imaging in detecting iodine-positive thyroid Cancer metastases. J Nucl Med. 2016;57:1339\u201342. https:\/\/doi.org\/10.2967\/jnumed.115.169649.","journal-title":"J Nucl Med"},{"key":"1138_CR19","doi-asserted-by":"publisher","unstructured":"Ros\u00e1rio PWS, Barroso \u00c1L, Rezende LL, Padr\u00e3o EL, Fagundes TA, Penna GC, Purisch S. Post I-131 therapy scanning in patients with thyroid carcinoma metastases: an unnecessary cost or a relevant Contribution? Clin Nucl Med. 2004;29. https:\/\/doi.org\/10.1097\/00003072-200412000-00005.","DOI":"10.1097\/00003072-200412000-00005"},{"key":"1138_CR20","doi-asserted-by":"publisher","first-page":"99","DOI":"10.4274\/mirt.37450","volume":"27","author":"A Oral","year":"2018","unstructured":"Oral A, Yaz\u0131c\u0131 B, Eraslan C, Burak Z. Unexpected false-positive I-131 uptake in patients with differentiated thyroid carcinoma. Mol Imaging Radionucl Ther. 2018;27:99\u2013106. https:\/\/doi.org\/10.4274\/mirt.37450.","journal-title":"Mol Imaging Radionucl Ther"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-024-01138-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-024-01138-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-024-01138-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T15:08:00Z","timestamp":1728400080000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmires.springeropen.com\/articles\/10.1186\/s13550-024-01138-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,8]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1138"],"URL":"https:\/\/doi.org\/10.1186\/s13550-024-01138-x","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,8]]},"assertion":[{"value":"17 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the institutional review board of Memorial Sloan Kettering Cancer Center, New York, USA (IRB #17\u2013315). Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SM. Larson reports receiving commercial research grants from Y-mAbs Therapeutics, Inc., Genentech, Inc., WILEX AG, Telix Pharmaceuticals Limited, and Regeneron Pharmaceuticals, Inc.; holding ownership interest\/equity in Elucida Oncology, Inc., and holding stock in ImaginAb, Inc., and Y-mAbs Therapeutics. SML is the inventor of issued patents both currently unlicensed and licensed by MSK to Samus Therapeutics, Inc., Elucida Oncology, Inc., and Y-mAbs Therapeutics, Inc. SML serves or has served as a consultant both compensated and uncompensated to Cynvec LLC, Eli Lilly & Co., Prescient Therapeutics Limited, Advanced Innovative Partners, LLC, Gerson Lehrman Group, Progenics Pharmaceuticals, Inc., Exini, Inc., and Janssen Pharmaceuticals, Inc. ALH relevant disclosures (over the last 3 years): serves as the principle investigator on clinical trials from AstraZeneca, Genentech, Merck, Bayer, Novartis, Celldex, Bristol-Meyer Squibb, Kura Oncology, Elevar Therapeutics, Astellas, Poseida Therapeutics, Bioatla, OncC4, and Ayala. ALH has served on advisory boards or performed consulting for Kura Oncology, Elevar Therapeutics, Prelude Therapeutics, Eisai, Exelixis, Merck, Rgenta, Remix Therapeutics, Cellestia, Inxmed, and Ayala. ALH serves on data and safety monitoring committees for Kura Oncology and Affyimmune Therapeutics. ALH is listed as an inventor on an MSK-issued patent for using lesional dosimetry methods for tailoring targeted radiotherapy in cancer.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"91"}}